Global Embolization Particle Sales 麻豆原创 Report, Competitive Analysis and Regional Opportunities 2025-2031

Publication ID:

PB504253524

Publication Date:

April 3, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 4,250.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global Embolization Particle market size was US$ 2633 million in 2024 and is forecast to a readjusted size of US$ 6708 million by 2031 with a CAGR of 14.5% during the forecast period 2025-2031.
Embolization Particle or embolisation refers to the passage and lodging of an embolus within the bloodstream. It may be pathological (in which sense it is also called embolism), for example a pulmonary embolism, or therapeutic, as a hemostatic treatment for bleeding or as a treatment for some types of cancer by deliberately blocking blood vessels to starve the tumor cells.
North America is the largest region of Embolization Particle, with a market share about 40%. It was followed by Europe with 30%. Sirtex Medical, Merit Medical, Cook Medical, BTG Medical and Boston Scientific Corporation are the top 5 manufacturers of industry, and they had about 80% combined market share.
The global Embolization Particle market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by Application for 2020-2031.
麻豆原创 Segmentation
By Company:
Sirtex Medical
Merit Medical
Cook Medical
BTG Medical
Boston Scientific Corporation
Terumo Corporation
HENGRUI Medical
INterface BIOmaterials B.V.
Alicon
By Type: (Dominant Segment vs High-Margin Innovation)
Microspheres
Particles (e.g. PVA Particles, Gelfoam Particles)
Drug-eluting Beads (DEBs)
Radio-Embolic Microspheres (e.g. Therasphere and SIRSphere)
By Application: (Core Demand Driver vs Emerging Opportunity)
Uterine Fibroid Embolization
Prostatic Artery Embolization (treatment for Benign Prostatic Hyperplasia or BPH)
Liver Tumor Embolization
Trauma Embolization
Others
By Region
Macro-Regional Analysis: 麻豆原创 Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local 麻豆原创 Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Sirtex Medical in Europe)
- Emerging Product Trends: Microspheres adoption vs. Particles (e.g. PVA Particles, Gelfoam Particles) premiumization
- Demand-Side Dynamics: Uterine Fibroid Embolization growth in China vs. Prostatic Artery Embolization (treatment for Benign Prostatic Hyperplasia or BPH) potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus 麻豆原创s:
North America
Europe
China
Australia
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Embolization Particle market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis 鈥� Uncovering blue ocean markets (e.g., Particles (e.g. PVA Particles, Gelfoam Particles) in China).
Chapter 5: Application-based segmentation analysis 鈥� High-growth downstream opportunities (e.g., Prostatic Artery Embolization (treatment for Benign Prostatic Hyperplasia or BPH) in India).
Chapter 6: Regional sales and revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles 鈥� Financials, product portfolios, and strategic developments.
Chapter 8: 麻豆原创 dynamics 鈥� Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
This is not just another market study. By fusing global trend analysis with hyper-local operational intelligence, we deliver:
- Risk-Controlled 麻豆原创 Entry: Navigate regulatory complexities in focus markets (e.g., China鈥檚 policies).
- Product Portfolio Optimization: Align offerings with regional preferences (e.g., Microspheres dominance in Europe vs. Particles (e.g. PVA Particles, Gelfoam Particles) demand in MEA).
- Competitor Counterstrategies: Decode player tactics in fragmented vs. consolidated markets.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Embolization Particle Product Scope
1.2 Embolization Particle by Type
1.2.1 Global Embolization Particle Sales by Type (2020 & 2024 & 2031)
1.2.2 Microspheres
1.2.3 Particles (e.g. PVA Particles, Gelfoam Particles)
1.2.4 Drug-eluting Beads (DEBs)
1.2.5 Radio-Embolic Microspheres (e.g. Therasphere and SIRSphere)
1.3 Embolization Particle by Application
1.3.1 Global Embolization Particle Sales Comparison by Application (2020 & 2024 & 2031)
1.3.2 Uterine Fibroid Embolization
1.3.3 Prostatic Artery Embolization (treatment for Benign Prostatic Hyperplasia or BPH)
1.3.4 Liver Tumor Embolization
1.3.5 Trauma Embolization
1.3.6 Others
1.4 Global Embolization Particle 麻豆原创 Estimates and Forecasts (2020-2031)
1.4.1 Global Embolization Particle 麻豆原创 Size in Value Growth Rate (2020-2031)
1.4.2 Global Embolization Particle 麻豆原创 Size in Volume Growth Rate (2020-2031)
1.4.3 Global Embolization Particle Price Trends (2020-2031)
1.5 Assumptions and Limitations
2 麻豆原创 Size and Prospective by Region
2.1 Global Embolization Particle 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
2.2 Global Embolization Particle Retrospective 麻豆原创 Scenario by Region (2020-2025)
2.2.1 Global Embolization Particle Sales 麻豆原创 Share by Region (2020-2025)
2.2.2 Global Embolization Particle Revenue 麻豆原创 Share by Region (2020-2025)
2.3 Global Embolization Particle 麻豆原创 Estimates and Forecasts by Region (2026-2031)
2.3.1 Global Embolization Particle Sales Estimates and Forecasts by Region (2026-2031)
2.3.2 Global Embolization Particle Revenue Forecast by Region (2026-2031)
2.4 Major Region and Emerging 麻豆原创 Analysis
2.4.1 North America Embolization Particle 麻豆原创 Size and Prospective (2020-2031)
2.4.2 Europe Embolization Particle 麻豆原创 Size and Prospective (2020-2031)
2.4.3 China Embolization Particle 麻豆原创 Size and Prospective (2020-2031)
2.4.4 Australia Embolization Particle 麻豆原创 Size and Prospective (2020-2031)
3 Global 麻豆原创 Size by Type
3.1 Global Embolization Particle Historic 麻豆原创 Review by Type (2020-2025)
3.1.1 Global Embolization Particle Sales by Type (2020-2025)
3.1.2 Global Embolization Particle Revenue by Type (2020-2025)
3.1.3 Global Embolization Particle Price by Type (2020-2025)
3.2 Global Embolization Particle 麻豆原创 Estimates and Forecasts by Type (2026-2031)
3.2.1 Global Embolization Particle Sales Forecast by Type (2026-2031)
3.2.2 Global Embolization Particle Revenue Forecast by Type (2026-2031)
3.2.3 Global Embolization Particle Price Forecast by Type (2026-2031)
3.3 Different Types Embolization Particle Representative Players
4 Global 麻豆原创 Size by Application
4.1 Global Embolization Particle Historic 麻豆原创 Review by Application (2020-2025)
4.1.1 Global Embolization Particle Sales by Application (2020-2025)
4.1.2 Global Embolization Particle Revenue by Application (2020-2025)
4.1.3 Global Embolization Particle Price by Application (2020-2025)
4.2 Global Embolization Particle 麻豆原创 Estimates and Forecasts by Application (2026-2031)
4.2.1 Global Embolization Particle Sales Forecast by Application (2026-2031)
4.2.2 Global Embolization Particle Revenue Forecast by Application (2026-2031)
4.2.3 Global Embolization Particle Price Forecast by Application (2026-2031)
4.3 New Sources of Growth in Embolization Particle Application
5 Competition Landscape by Players
5.1 Global Embolization Particle Sales by Players (2020-2025)
5.2 Global Top Embolization Particle Players by Revenue (2020-2025)
5.3 Global Embolization Particle 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Embolization Particle as of 2024)
5.4 Global Embolization Particle Average Price by Company (2020-2025)
5.5 Global Key Manufacturers of Embolization Particle, Manufacturing Sites & Headquarters
5.6 Global Key Manufacturers of Embolization Particle, Product Type & Application
5.7 Global Key Manufacturers of Embolization Particle, Date of Enter into This Industry
5.8 Manufacturers Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America 麻豆原创: Players, Segments, Downstream and Major Customers
6.1.1 North America Embolization Particle Sales by Company
6.1.1.1 North America Embolization Particle Sales by Company (2020-2025)
6.1.1.2 North America Embolization Particle Revenue by Company (2020-2025)
6.1.2 North America Embolization Particle Sales Breakdown by Type (2020-2025)
6.1.3 North America Embolization Particle Sales Breakdown by Application (2020-2025)
6.1.4 North America Embolization Particle Major Customer
6.1.5 North America 麻豆原创 Trend and Opportunities
6.2 Europe 麻豆原创: Players, Segments, Downstream and Major Customers
6.2.1 Europe Embolization Particle Sales by Company
6.2.1.1 Europe Embolization Particle Sales by Company (2020-2025)
6.2.1.2 Europe Embolization Particle Revenue by Company (2020-2025)
6.2.2 Europe Embolization Particle Sales Breakdown by Type (2020-2025)
6.2.3 Europe Embolization Particle Sales Breakdown by Application (2020-2025)
6.2.4 Europe Embolization Particle Major Customer
6.2.5 Europe 麻豆原创 Trend and Opportunities
6.3 China 麻豆原创: Players, Segments, Downstream and Major Customers
6.3.1 China Embolization Particle Sales by Company
6.3.1.1 China Embolization Particle Sales by Company (2020-2025)
6.3.1.2 China Embolization Particle Revenue by Company (2020-2025)
6.3.2 China Embolization Particle Sales Breakdown by Type (2020-2025)
6.3.3 China Embolization Particle Sales Breakdown by Application (2020-2025)
6.3.4 China Embolization Particle Major Customer
6.3.5 China 麻豆原创 Trend and Opportunities
6.4 Australia 麻豆原创: Players, Segments, Downstream and Major Customers
6.4.1 Australia Embolization Particle Sales by Company
6.4.1.1 Australia Embolization Particle Sales by Company (2020-2025)
6.4.1.2 Australia Embolization Particle Revenue by Company (2020-2025)
6.4.2 Australia Embolization Particle Sales Breakdown by Type (2020-2025)
6.4.3 Australia Embolization Particle Sales Breakdown by Application (2020-2025)
6.4.4 Australia Embolization Particle Major Customer
6.4.5 Australia 麻豆原创 Trend and Opportunities
7 Company Profiles and Key Figures
7.1 Sirtex Medical
7.1.1 Sirtex Medical Company Information
7.1.2 Sirtex Medical Business Overview
7.1.3 Sirtex Medical Embolization Particle Sales, Revenue and Gross Margin (2020-2025)
7.1.4 Sirtex Medical Embolization Particle Products Offered
7.1.5 Sirtex Medical Recent Development
7.2 Merit Medical
7.2.1 Merit Medical Company Information
7.2.2 Merit Medical Business Overview
7.2.3 Merit Medical Embolization Particle Sales, Revenue and Gross Margin (2020-2025)
7.2.4 Merit Medical Embolization Particle Products Offered
7.2.5 Merit Medical Recent Development
7.3 Cook Medical
7.3.1 Cook Medical Company Information
7.3.2 Cook Medical Business Overview
7.3.3 Cook Medical Embolization Particle Sales, Revenue and Gross Margin (2020-2025)
7.3.4 Cook Medical Embolization Particle Products Offered
7.3.5 Cook Medical Recent Development
7.4 BTG Medical
7.4.1 BTG Medical Company Information
7.4.2 BTG Medical Business Overview
7.4.3 BTG Medical Embolization Particle Sales, Revenue and Gross Margin (2020-2025)
7.4.4 BTG Medical Embolization Particle Products Offered
7.4.5 BTG Medical Recent Development
7.5 Boston Scientific Corporation
7.5.1 Boston Scientific Corporation Company Information
7.5.2 Boston Scientific Corporation Business Overview
7.5.3 Boston Scientific Corporation Embolization Particle Sales, Revenue and Gross Margin (2020-2025)
7.5.4 Boston Scientific Corporation Embolization Particle Products Offered
7.5.5 Boston Scientific Corporation Recent Development
7.6 Terumo Corporation
7.6.1 Terumo Corporation Company Information
7.6.2 Terumo Corporation Business Overview
7.6.3 Terumo Corporation Embolization Particle Sales, Revenue and Gross Margin (2020-2025)
7.6.4 Terumo Corporation Embolization Particle Products Offered
7.6.5 Terumo Corporation Recent Development
7.7 HENGRUI Medical
7.7.1 HENGRUI Medical Company Information
7.7.2 HENGRUI Medical Business Overview
7.7.3 HENGRUI Medical Embolization Particle Sales, Revenue and Gross Margin (2020-2025)
7.7.4 HENGRUI Medical Embolization Particle Products Offered
7.7.5 HENGRUI Medical Recent Development
7.8 INterface BIOmaterials B.V.
7.8.1 INterface BIOmaterials B.V. Company Information
7.8.2 INterface BIOmaterials B.V. Business Overview
7.8.3 INterface BIOmaterials B.V. Embolization Particle Sales, Revenue and Gross Margin (2020-2025)
7.8.4 INterface BIOmaterials B.V. Embolization Particle Products Offered
7.8.5 INterface BIOmaterials B.V. Recent Development
7.9 Alicon
7.9.1 Alicon Company Information
7.9.2 Alicon Business Overview
7.9.3 Alicon Embolization Particle Sales, Revenue and Gross Margin (2020-2025)
7.9.4 Alicon Embolization Particle Products Offered
7.9.5 Alicon Recent Development
8 Embolization Particle Manufacturing Cost Analysis
8.1 Embolization Particle Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Embolization Particle
8.4 Embolization Particle Industrial Chain Analysis
9 麻豆原创ing Channel, Distributors and Customers
9.1 麻豆原创ing Channel
9.2 Embolization Particle Distributors List
9.3 Embolization Particle Customers
10 Embolization Particle 麻豆原创 Dynamics
10.1 Embolization Particle Industry Trends
10.2 Embolization Particle 麻豆原创 Drivers
10.3 Embolization Particle 麻豆原创 Challenges
10.4 Embolization Particle 麻豆原创 Restraints
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.1.1 Research Programs/Design
12.1.1.2 麻豆原创 Size Estimation
12.1.1.3 麻豆原创 Breakdown and Data Triangulation
12.1.2 Data Source
12.1.2.1 Secondary Sources
12.1.2.2 Primary Sources
12.2 Author Details
12.3 Disclaimer

Companies Mentioned:

Sirtex Medical
Merit Medical
Cook Medical
BTG Medical
Boston Scientific Corporation
Terumo Corporation
HENGRUI Medical
INterface BIOmaterials B.V.
Alicon

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.